But the realisation of a successful inhaler is an immensely complex task. For example, selecting the right technical approach for your drug, and the decision to either design your own device or to source a third party will have a major impact on project success. Also, sub-optimal product testing during development and in manufacturing can drive costs up and cause substantial programme delays. Lack of a robust manufacturing strategy can further delay the launch of your product.
How can the pitfalls of inhaler development be avoided and best practice be achieved?
PA Consulting Group has a proven track record of delivering inhalation solutions from concept right through to launch and can provide you with all the support you need to achieve the best possible development programme. With more than 25 years of experience of product and process development in the pharmaceutical sector, we remain at the forefront of technological innovation in the field of inhalatory medicine.
* Datamonitor Commercial Insight: Asthma & COPD – On the verge of generic entry, June 2009
For a major pharmaceutical company, PA was responsible for the design and development of a novel breath actuated inhaler.
PA has undertaken a State of the Art review of dose counter mechanisms within the inhalation market.
For a major US pharmaceutical company, PA developed a highly accurate product testing system to automate a manual Emitted Dose Test.
Following the success of its respiratory drug delivery technology platform a US-based inhalation technology company asked PA to advise on its strategy for the next 10 years.
PA worked with a pharmaceutical client new to medical devices to manage the quality and development project for its pulmonary device.
To find out more about our drug delivery strategy and product development services, please contact us now.